Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

GLP1R Variants and Weight Loss Response

Rare GLP1R variants were linked to less weight loss with semaglutide, while a small tirzepatide carrier group had a near-normal response.

Why we wrote this. The drug-specific genetic association is easy to overread as a treatment test. We separate the observed cohorts from causal prediction and clinical actionability.

In this article (5 sections)
  1. How the pharmacogenetic study worked
  2. The semaglutide association was large
  3. Tirzepatide showed a different pattern
  4. Why this is not a treatment-selection test
  5. What we don't yet know

Rare GLP1R variants attenuated weight loss with semaglutide but not tirzepatide in a 2026 observational pharmacogenetic study. Among 17 semaglutide-treated carriers, mean weight loss was 2.4%, compared with 8.8% in matched non-carriers. Among 19 tirzepatide-treated carriers, the corresponding averages were 13.3% and 15.2%[3]. This is an association from routine-care records. It is not a validated genetic test for choosing treatment.

The paper combined exome sequencing with electronic health records and insurance claims from the Helix Research Network. It included 13,725 adults who began subcutaneous semaglutide or tirzepatide in routine care and had at least six months of on-treatment weight follow-up[1]. The design was a retrospective cohort study, not a randomized comparison of the two medicines.

How the pharmacogenetic study worked

The wider network contained sequencing and health-record data for 351,818 people across 13 North American health systems. Eligible treated adults had a baseline body mass index of at least 25 and a weight recorded within six months before treatment. The primary outcome used the lowest recorded on-treatment weight between 6 and 12 months[3]. Using the lowest value may differ from an endpoint based on a fixed visit.

Researchers classified rare coding variants in GLP1R and GIPR by predicted consequence. The qualifying GLP1R group combined predicted loss-of-function variants with missense variants rated damaging or possibly damaging by computational tools. One variant also had prior cell-based evidence of reduced receptor signalling. Most individual variants had fewer than five carriers[3]. Prediction scores are evidence about likely function, not direct proof that every included variant changes a person's drug response.

Of the 13,725 treated adults, 33 carried a qualifying rare GLP1R variant. Each carrier was matched with up to ten non-carriers on medicine, highest recorded dose, sex, type 2 diabetes, previous GLP-1 medicine use, genetic similarity group, baseline body mass index and follow-up duration[2]. Matching can balance recorded factors. It cannot remove confounding from adherence, care decisions or other unmeasured differences.

The semaglutide association was large

Across both medicines, GLP1R carriers lost 8.2% of body weight on average, versus 12.5% among matched non-carriers. The drug-specific result was sharper for semaglutide. Its 17 carrier episodes had 2.4% mean weight loss, compared with 8.8% for matched non-carriers. The response ratio was 0.27, with a reported P value of 0.0007[3]. Fifteen of the 17 carriers lost less than the average of their own matched sets.

A separate All of Us analysis identified only eight eligible semaglutide-treated carriers. Their mean changes were minus 2.6% versus minus 5.7% in matched non-carriers, a directionally similar result that was not statistically conclusive (P = 0.12). A newer, non-overlapping Helix cohort included seven semaglutide carriers and again found attenuation, minus 4.1% versus minus 7.5%[3]. These small replication counts support further study rather than precise variant-level prediction.

Tirzepatide showed a different pattern

The 19 tirzepatide-treated GLP1R carrier episodes lost 13.3% on average, compared with 15.2% in matched non-carriers. The response ratio was 0.88 and the P value was 0.23[3]. That result did not show the large attenuation seen with semaglutide, but a non-significant comparison does not prove identical responses or rule out a smaller effect.

The carrier-by-drug interaction estimated a 4.4 percentage-point difference in the carrier effect, with a 95% confidence interval from 1.1 to 7.7 percentage points and P = 0.009. The newer Helix cohort also reproduced the drug-specific pattern using seven semaglutide and 11 tirzepatide carriers[3]. Some people used both medicines sequentially, so drug-specific episodes should not be added as if they were 36 unique carriers.

Tirzepatide activates both GLP-1 and GIP receptors, which gives the finding a plausible biological explanation. Still, this study did not experimentally show that GIP receptor activity compensated for impaired GLP-1 receptor function. The authors call direct experimental evidence necessary. The most severe GLP1R variant classes also showed possible attenuation with tirzepatide in a small subgroup[3].

Why this is not a treatment-selection test

The results link genotype with average weight change under observed care. They do not show that testing people for GLP1R variants and assigning tirzepatide improves outcomes. No prospective genotype-guided strategy was compared with ordinary clinical care, and no treatment-selection rule was externally validated. The qualifying variants appeared in about 0.2% of treated participants[3].

The carrier count was small and predominantly from people genetically similar to European reference populations. Medication use and weight came from routine records, while variant classification relied partly on computational predictions. Non-coding and structural variants were not assessed. These limits make an individual forecast much less certain than the group averages suggest[3].

A rare-variant result should not be used on its own to request a medicine, switch treatment or interpret a disappointing response. Current treatment decisions still require a clinician to consider indication, medical history, adverse effects, access and the response actually observed.

What we don't yet know

Larger studies are needed to estimate effects for individual variants and for people from more diverse ancestry groups. Researchers also need direct functional work on the included variants, prospective replication and a trial of any proposed genotype-guided decision rule. Those steps would test whether the association can become useful clinical prediction rather than an interesting population finding.

The study separates the semaglutide and tirzepatide patterns more clearly than earlier class-wide genetic analyses. Its strongest conclusion is narrow: rare GLP1R carrier status was associated with substantially less weight loss during semaglutide treatment in these records, while the small tirzepatide carrier group had a near-normal average response. Causation, individual prediction and clinical actionability remain unsettled.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.

Frequently asked

What did the GLP1R variant study find?

Rare GLP1R variant carriers had less average weight loss than matched non-carriers during semaglutide treatment. The small tirzepatide carrier group had a near-normal average response.

Was this a randomized semaglutide-versus-tirzepatide trial?

No. It was a retrospective pharmacogenetic cohort using sequencing, health records and claims. Carrier status and treatment were not randomly assigned.

Does a rare GLP1R variant prove semaglutide will not work?

No. The findings are group-level associations from very small carrier samples. They do not determine an individual's response or prove that genotype caused it.

Should these results guide genetic testing or a treatment switch?

Not on their own. No prospective genotype-guided strategy or treatment-selection rule was validated, so the paper does not establish a clinical testing or switching recommendation.

Sources

  1. [1]Levy et al. Rare GLP1R variants attenuate weight loss with semaglutide but not tirzepatide. PMID 43015368.Tier 1 · primary↩
  2. [2]NCBI PubMed EFetch structured record for PMID 43015368.Tier 1 · primary↩
  3. [3]Levy et al. Nature Metabolism full text and methods (2026).Tier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.

Read the pillars